Try the Free App:
Prime PubMed app for iOS iPhone iPad
Prime PubMed app for Android
Prime PubMed is provided
free to individuals by:
Unbound Medicine.
(Remdesivir AND ("Novel Coronavirus" OR COVID-19 OR SARS-CoV-2 OR 2019-nCoV))
1,374 results
  • Use of Remdesivir in Myasthenia Gravis and COVID-19. [Case Reports]
    Pharmacotherapy. 2021 Apr 09 [Online ahead of print]Peters BJ, Rabinstein AA, DuBrock HM
  • Myasthenia gravis and the associated pharmacologic management options could place patients at higher risk of contracting severe acute respiratory syndrome coronavirus 2 and exhibiting more severe manifestations of the novel coronavirus disease 2019 (COVID-19). Multiple agents have been studied for the management of the COVID-19, including remdesivir. To date, no published reports have evaluated t…
  • Construction of Non-infectious SARS-CoV-2 Replicons and Their Application in Drug Evaluation. [Journal Article]
    Virol Sin. 2021 Apr 09 [Online ahead of print]Wang B, Zhang C, … Huang H
  • Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has caused a devastating pandemic worldwide. Vaccines and antiviral drugs are the most promising candidates for combating this global epidemic, and scientists all over the world have made great efforts to this end. However, manipulation of the SARS-CoV-2 should be performed in the biosafety level 3 laboratory. This makes experiments com…
  • SARS-CoV-2 and Human Immunodeficiency Virus: Pathogen Pincer Attack. [Review]
    HIV AIDS (Auckl). 2021; 13:361-375.Evans N, Martinez E, … Almodovar S
  • Paramount efforts worldwide are seeking to increase understanding of the basic virology of SARS-CoV-2, characterize the spectrum of complications associated with COVID-19, and develop vaccines that can protect from new and recurrent infections with SARS-CoV-2. While we continue learning about this new virus, it is clear that 1) the virus is spread via the respiratory route, primarily by droplets …
  • SARS-CoV-2 drives JAK1/2-dependent local complement hyperactivation. [Journal Article]
    Sci Immunol. 2021 Apr 07; 6(58)Yan B, Freiwald T, … Kazemian M
  • Patients with coronavirus disease 2019 (COVID-19) present a wide range of acute clinical manifestations affecting the lungs, liver, kidneys and gut. Angiotensin converting enzyme (ACE) 2, the best-characterized entry receptor for the disease-causing virus SARS-CoV-2, is highly expressed in the aforementioned tissues. However, the pathways that underlie the disease are still poorly understood. Her…
  • Discovery and in-vitro evaluation of potent SARS-CoV-2 entry inhibitors. [Preprint]
    bioRxiv. 2021 Apr 02Acharya A, Pandey K, … Byrareddy SN
  • SARS-CoV-2 infection initiates with the attachment of spike protein to the ACE2 receptor. While vaccines have been developed, no SARS-CoV-2 specific small molecule inhibitors have been approved. Herein, utilizing the crystal structure of the ACE2/Spike receptor binding domain (S-RBD) complex in computer-aided drug design (CADD) approach, we docked ∼8 million compounds within the pockets residing …
  • The FDA and the COVID-19: A political economy perspective. [Journal Article]
    South Econ J. 2021 Feb 28 [Online ahead of print]March RJ
  • This article utilizes a political economy framework to examine how FDA regulations impacted the U.S. healthcare sector's ability to address COVID-19. I specifically examine the developing COVID-19 testing, the approval of the medication remdesivir, and COVID-19 vaccines. By examining periods before and after the FDA issued Emergency Use Authorizations (EUAs), my analysis finds that the FDA's regu…
  • Drugs intervention study in COVID-19 management. [Review]
    Drug Metab Pers Ther. 2021 Apr 05 [Online ahead of print]Taher M, Tik N, Susanti D
  • By 9 February 2021, the Coronavirus has killed 2,336,650 people worldwide and it has been predicted that this number continues to increase in year 2021. The study aimed to identify therapeutic approaches and drugs that can potentially be used as interventions in Coronavirus 2019 (COVID-19) management. A systematic scoping review was conducted. Articles reporting clinical evidence of therapeutic m…
  • Potential anti-COVID-19 agents, Cepharanthine and Nelfinavir, and their usage for combination treatment. [Journal Article]
    iScience. 2021 Mar 26 [Online ahead of print]Ohashi H, Watashi K, … Wakita T
  • Antiviral treatments targeting the coronavirus disease 2019 are urgently required. We screened a panel of already-approved drugs in a cell culture model of severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) and identified two new agents having higher antiviral potentials than the drug candidates such as Remdesivir and Chroloquine in VeroE6/TMPRSS2 cells: the anti-inflammatory drug Cepha…
  • An Overview of Current Knowledge of Deadly CoVs and Their Interface with Innate Immunity. [Review]
    Viruses. 2021 03 26; 13(4)Zhang Y, Gargan S, … Stevenson NJ
  • Coronaviruses are a large family of zoonotic RNA viruses, whose infection can lead to mild or lethal respiratory tract disease. Severe Acute Respiratory Syndrome-Coronavirus-1 (SARS-CoV-1) first emerged in Guangdong, China in 2002 and spread to 29 countries, infecting 8089 individuals and causing 774 deaths. In 2012, Middle East Respiratory Syndrome-Coronavirus (MERS-CoV) emerged in Saudi Arabia …
  • Rapamycin: Drug Repurposing in SARS-CoV-2 Infection. [Review]
    Pharmaceuticals (Basel). 2021 Mar 05; 14(3)Patocka J, Kuca K, … Klimova B
  • Since December 2019, SARS-CoV-2 (COVID-19) has been a worldwide pandemic with enormous consequences for human health and the world economy. Remdesivir is the only drug in the world that has been approved for the treating of COVID-19. This drug, as well as vaccination, still has uncertain effectiveness. Drug repurposing could be a promising strategy how to find an appropriate molecule: rapamycin c…
  • Pharmacogenetics Approach for the Improvement of COVID-19 Treatment. [Review]
    Viruses. 2021 03 05; 13(3)Fricke-Galindo I, Falfán-Valencia R
  • The treatment of coronavirus disease 2019 (COVID-19) has been a challenge. The efficacy of several drugs has been evaluated and variability in drug response has been observed. Pharmacogenetics could explain this variation and improve patients' outcomes with this complex disease; nevertheless, several disease-related issues must be carefully reviewed in the pharmacogenetic study of COVID-19 treatm…
  • Interaction of Remdesivir with Clinically Relevant Hepatic Drug Uptake Transporters. [Journal Article]
    Pharmaceutics. 2021 Mar 10; 13(3)Nies AT, König J, … Schwab M
  • Remdesivir has been approved for treatment of COVID-19 and shortens the time to recovery in hospitalized patients. Drug transporters removing remdesivir from the circulation may reduce efficacy of treatment by lowering its plasma levels. Information on the interaction of remdesivir with drug transporters is limited. We therefore assessed remdesivir as substrate and inhibitor of the clinically rel…
  • COVID-19, a tale of two peaks: patients' characteristics, treatments, and clinical outcomes. [Journal Article]
    Intern Emerg Med. 2021 Apr 01 [Online ahead of print]Banai A, Taieb P, … Szekely Y
  • Coronavirus 2019 disease (COVID-19) continues to challenge healthcare systems globally as many countries are currently experiencing an increase in the morbidity and mortality. Compare baseline characteristics, clinical presentation, treatments, and clinical outcomes of patients admitted during the second peak to those admitted during the first peak. Retrospective analysis of 258 COVID-19 patients…
  • Management considerations for stroke-like episodes in MELAS with concurrent COVID-19 infection. [Journal Article]
    J Neurol. 2021 Apr 01 [Online ahead of print]Sen K, Harrar D, … Gropman AL
  • There have been considerations since the beginning of the Coronavirus pandemic that COVID-19 infection, like any other viral illness, can trigger neurological and metabolic decompensation in patients with mitochondrial diseases. At the time of writing, there were no published reports reviewing experiences and guidelines about management of COVID-19 infection in this patient population. We present…
New Search Next